Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016 Kerry Rowe

Abstract from Movement Disorders Conference 2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Alterity in the news: Herald Sun

May 27, 2019July 10, 2019

Prana AGM Investor Conference Call

November 11, 2018

European Commission Approves PBT2 Orphan Designation for Huntington’s Disease

June 1, 2015

Recent Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065